H Li1, Z Jin1, X Li1, L Wu1, J Jin2. 1. Department of Digestive Medicine, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, No. 24 Jinghua Road, Jianxi District, Luoyang, 471003, Henan, China. 2. Department of Digestive Medicine, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, No. 24 Jinghua Road, Jianxi District, Luoyang, 471003, Henan, China. jianjun713@sina.com.
Abstract
PURPOSE: To assess the correlation between single-nucleotide polymorphisms (SNPs) and inflammatory bowel disease (IBD)-associated colorectal cancer (CRC) in IBD patients. METHODS: A systematic search of PubMed, EmBase, and Cochrane databases was performed. Five genetic models (allelic, dominant, recessive, heterozygous and homozygous models) were used to analyze the associations, and trial sequential analysis was used to analyze the robustness of the results. RESULTS: We collected and analyzed the results of seven trials including a total of 2287 patients in our meta-analysis. A total of 8 SNPs were tested in IBD patients. For rs1800629 of TNF-α, the allelic model showed that polymorphism at this locus significantly increased the risk of IBD-associated CRC in IBD patients (OR 4.45, 95% CI 3.18-6.21, P < 0.001). The results also showed a significant association between rs1800629 and an IBD-associated CRC population (heterozygous model: OR 4.335, 95% CI 2.329-8.069, P < 0.001; homozygous model: OR 11.5, 95% CI 2.498-52.592, P = 0.002; dominant model: OR 4.986, 95% CI 2.754-9.026, P < 0.001; recessive model: OR 7.208, 95% CI 1.588-32.72, P = 0.01). Other studies have found that mutation of rs1143627 of IL1B (allelic model: OR 2.97; 95% CI 1.74-5.05, P < 0.001) and rs1050152 of OCTN1 (allelic model: OR 1.637, 95% CI 1.078-2.485, P = 0.021) increased the proportion of IBD-associated CRC in the population. Moreover, there were significant associations between IBD-associated CRC and ITLN rs2274910, gene desert rs1551398 and rs4871611, FCGR2A rs1801274, and S100-Z rs7712957 in the allelic model. CONCLUSION: Associations between SNPs and the proportion of IBD-associated CRC in IBD patients were examined, and further investigation of additional SNPs and their association with the risk of morbidity is needed.
PURPOSE: To assess the correlation between single-nucleotide polymorphisms (SNPs) and inflammatory bowel disease (IBD)-associated colorectal cancer (CRC) in IBD patients. METHODS: A systematic search of PubMed, EmBase, and Cochrane databases was performed. Five genetic models (allelic, dominant, recessive, heterozygous and homozygous models) were used to analyze the associations, and trial sequential analysis was used to analyze the robustness of the results. RESULTS: We collected and analyzed the results of seven trials including a total of 2287 patients in our meta-analysis. A total of 8 SNPs were tested in IBD patients. For rs1800629 of TNF-α, the allelic model showed that polymorphism at this locus significantly increased the risk of IBD-associated CRC in IBD patients (OR 4.45, 95% CI 3.18-6.21, P < 0.001). The results also showed a significant association between rs1800629 and an IBD-associated CRC population (heterozygous model: OR 4.335, 95% CI 2.329-8.069, P < 0.001; homozygous model: OR 11.5, 95% CI 2.498-52.592, P = 0.002; dominant model: OR 4.986, 95% CI 2.754-9.026, P < 0.001; recessive model: OR 7.208, 95% CI 1.588-32.72, P = 0.01). Other studies have found that mutation of rs1143627 of IL1B (allelic model: OR 2.97; 95% CI 1.74-5.05, P < 0.001) and rs1050152 of OCTN1 (allelic model: OR 1.637, 95% CI 1.078-2.485, P = 0.021) increased the proportion of IBD-associated CRC in the population. Moreover, there were significant associations between IBD-associated CRC and ITLNrs2274910, gene desert rs1551398 and rs4871611, FCGR2Ars1801274, and S100-Z rs7712957 in the allelic model. CONCLUSION: Associations between SNPs and the proportion of IBD-associated CRC in IBD patients were examined, and further investigation of additional SNPs and their association with the risk of morbidity is needed.
Authors: Alberto Fernández; Vicent Hernández; David Martínez-Ares; Luciano Sanromán; María Luisa de Castro; Juan Ramón Pineda; Amalia Carmona; Carlos González-Portela; Carlos Salgado; Jesús Martínez-Cadilla; Santos Pereira; Jose Ignacio García-Burriel; Santiago Vázquez; Ignacio Rodríguez-Prada Journal: Gastroenterol Hepatol Date: 2015-04-15 Impact factor: 2.102
Authors: Megan M Garrity-Park; Edward V Loftus; Sandra C Bryant; William J Sandborn; Thomas C Smyrk Journal: Am J Gastroenterol Date: 2008-02 Impact factor: 10.864
Authors: Sabrina Angelini; Maria Abbondanza Pantaleo; Gloria Ravegnini; Corrado Zenesini; Giulia Cavrini; Margherita Nannini; Elena Fumagalli; Elena Palassini; Maristella Saponara; Monica Di Battista; Paolo G Casali; Patrizia Hrelia; Giorgio Cantelli-Forti; Guido Biasco Journal: Pharmacol Res Date: 2012-11-02 Impact factor: 7.658
Authors: Cecília Durães; José C Machado; Francisco Portela; Susana Rodrigues; Paula Lago; Marília Cravo; Paula Ministro; Margarida Marques; Isabelle Cremers; João Freitas; José Cotter; Lurdes Tavares; Leopoldo Matos; Isabel Medeiros; Rui Sousa; Jaime Ramos; João Deus; Paulo Caldeira; Cristina Chagas; Maria A Duarte; Raquel Gonçalves; Rui Loureiro; Luísa Barros; Isabel Bastos; Eugénia Cancela; Mário C Moraes; Maria J Moreira; Ana I Vieira; Fernando Magro Journal: Inflamm Bowel Dis Date: 2013-02 Impact factor: 5.325
Authors: Maryam H Alrashid; Ahmad Al-Serri; Salem H Alshemmari; Jeethu Anu Geo; Suzanne A Al-Bustan Journal: Cancer Biomark Date: 2021 Impact factor: 4.388